TP53 and acute lymphoblastic leukemia: In fact, adavosertib exposure led to a significant decrease in leukemic blast survival in the vast majority of the primary and primary-derived ALL specimens investigated at concentrations safely attained in clinical studies [26, 27, 30], irrespective of TP53 mutation status and in the absence of any additional exogenous stress.